NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - - Overall ...
- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing ...
A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...
Racial disparities and survival outcomes in secondary acute myeloid leukemia: A SEER-based analysis.
Venetoclax/azacitidine vs intensive chemotherapy as a bridge to allogeneic HSCT in AML: Experience from Ukraine. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Decoding immune dysregulation in AML: Insights from integrated genomic and transcriptomic analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results